Mosunetuzumab (BTCT-4465A) 是一种人源化、基于免疫球蛋白 G1 的双特异性抗体，靶向CD20(B 细胞) 和CD3(T 细胞)。Mosunetuzumab 重定向 T 细胞以接合和消除恶性 B 细胞，可用于研究复发或难治性 (R/R) B 细胞非霍奇金淋巴瘤 (B-NHL)。
| 生物活性 | Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targetingCD20(B cells) andCD3(T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
